FDA quietly turns three Keytruda accelerated approvals into full approvals

Merck’s anti-PD-1 antibody blockbuster Keytruda had three accelerated approvals converted into full approvals on Dec. 16.

The accelerated approvals were originally granted in 2020, and allowed for dosing of patients once every six weeks with 400 mg of the drug, as opposed to 200 mg every three weeks. The indications being converted to full approval include:

• The alternative dosing schedule for patients with a wide variety of cancer types including head and neck cancer, gastric cancer, melanoma and others
• The alternative dosing schedule for adult patients with metastatic or unresectable cancers with a high mutation burden in solid tumors
• The alternative dosing schedule for patients with cutaneous squamous cell carcinoma

The FDA’s approval letter to Merck noted that the full approval was given based on an analysis of overall response rate, duration of response, and safety from one of the cohorts of the KEYNOTE-555 trial, a Phase I randomized trial of pembrolizumab to evaluate bioavailability of the dosing regimen.

Scot Ebbinghaus

“The six-week dosing schedule for KEYTRUDA has provided physicians and patients with greater flexibility in their treatment plans. As part of our commitment to improving the lives of people living with cancer, we are excited that KEYTRUDA was granted a full approval for the six-week dosing option across solid tumors,” Merck clinical research VP Scot Ebbinghaus told Endpoints News via email.

A Merck spokesperson said that while those three approvals were converted, there is still one remaining for that dose regimen change in adult classical Hodgkin lymphoma and adult primary mediastinal large B cell lymphoma.

fda
research
clinical research